Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Connect Biopharma shared strong financial results and significant clinical progress in 2025 and early 2026 for rademikibart, their lead drug candidate targeting inflammatory diseases such as asthma, COPD, and atopic dermatitis. The company reported positive Phase 1 clinical data showing rapid and sustained lung function improvement with IV rademiki…